MedTrace Logo

UWCCC Molecular Tumor Board Registry

NCT03023202 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-04-13

No results posted yet for this study

Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Conditions

  • Hematologic Neoplasms
  • Solid Neoplasm

Interventions

OTHER

PMMTB (Precision Medicine Molecular Tumor Board)

PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Dustin Deming, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-30
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023202 on ClinicalTrials.gov